Valvular & structural heart diseaseCohort study

Association of Baseline Tricuspid Regurgitation With Health Status and Clinical Outcomes After Transcatheter Aortic Valve Replacement (TAVR) and Mitral TEER

JACC Cardiovasc IntervPublished

  • Registry-based cohort study
  • STS/ACC TVT Registry

Authors' conclusion

In a large cohort of U.S. patients who underwent TAVR or M-TEER, greater baseline TR was associated with worse health status and clinical outcomes.

Study context

Population
Patients in the TVT Registry undergoing isolated TAVR or mitral transcatheter edge-to-edge repair (M-TEER), January 2019–June 2021130,097 TAVR
Exposure
Severe vs moderate vs none-to-mild baseline tricuspid regurgitation (TR)
Outcome
Health status (Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score), being alive and well, and clinical outcomes by baseline TR

Main finding

As reported in the abstract

Baseline KCCQ-OS score · baseline
GroupValueM-TEER
Severe TRmean 39.4 (SD 24.2)38.1 ± 23.9
Moderate TRmean 45.2 (SD 24.7)41.9 ± 24.7
None to mild TRmean 51.3 (SD 25.3)45.4 ± 25.2
Trend across TR groups, TAVR
P < 0.01
Trend across TR groups, M-TEER
P < 0.01

Observational data: associations, not effects.

Further findings

Outcomeadjusted OR (95% CI)
Alive and well · 1 year — Moderate TR vs None to mild TR · TAVR0.79 (0.74–0.85)
Alive and well · 1 year — Severe TR vs None to mild TR · TAVR0.81 (0.70–0.94)
Alive and well · 1 year — Severe TR vs None to mild TR · M-TEER0.53 (0.40–0.71)

1-year mortality and readmission

Moderate or severe TR before TAVR associated with higher 1-year mortality and readmission
Moderate or severe TR before M-TEER associated with higher 1-year mortality

Original publication

Association of Baseline Tricuspid Regurgitation With Health Status and Clinical Outcomes After TAVR and Mitral TEER. JACC Cardiovasc Interv. Published 26 August 2024. doi:10.1016/j.jcin.2024.05.029

Summarised from the published abstract; every number is checked against it